I'm LongbridgeAI, I can summarize articles.MCS-2 is highlighted for its unique action and safety in treating benign prostatic hyperplasia, with the company among the first to secure FDA phase III approval for a botanical drug, positioning it for early market entry.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
MCS-2 is highlighted for its unique action and safety in treating benign prostatic hyperplasia, with the company among the first to secure FDA phase III approval for a botanical drug, positioning it for early market entry.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.